| Autor: |
PAPANIKOLAOU, VASILEIOS, KYRODIMOS, EFTHYMIOS, MASTRONIKOLIS, NICHOLAS, ASIMAKOPOULOS, ASIMAKIS D., PAPANASTASIOU, GEORGE, TSIAMBAS, EVANGELOS, SPYROPOULOU, DESPOINA, KATSINIS, SPYROS, MANOLI, AREZINA, PAPOULIAKOS, SOTIRIOS, PANTOS, PAVLOS, RAGOS, VASILEIOS, PESCHOS, DIMITRIOS, CHRYSOVERGIS, ARISTEIDIS |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Cancer Diagn Progn |
| ISSN: |
2732-7787 |
| DOI: |
10.21873/cdp.10194 |
| Popis: |
Alterations in significant genes located on chromosome 7 - including epidermal growth factor receptor (EGFR) and also v-Raf murine sarcoma viral oncogene homolog B (BRAF) as a mitogen-activated protein kinase (MAPK) - combined or not with numerical imbalances of the whole chromosome (aneuploidy-polysomy) are crucial genetic events involved in the development and progression of malignancies. Identification of EGFR/BRAF-dependent specific somatic mutations and other mechanisms of deregulation (i.e., amplification) is critical for applying targeted therapeutic approaches [tyrosine kinase inhibitors (TKIs] or monoclonal antibodies (mAbs). Thyroid carcinoma is a specific pathological entity characterized by a variety of histological sub-types. Follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC) represent its main sub-types. In the current review, we explore the role of EGFR/BRAF alterations in thyroid carcinoma in conjunction with the corresponding anti-EGFR/BRAF TKI-based novel therapeutic strategies for patients with specific genetic signatures. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
